Delivery Order SPE2DB24D2205-SPE2DB25FEDDZ
- Not listed
- The Defense Logistics Agency awarded a $20,139.90 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of August 27, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $13,541.70 delivery order to AmerisourceBergen Drug Corp for Ozempic (0.25-0.5 mg/dose pen, 3ml) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $9,751.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL). The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $36,663.92 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 25, 2025, with completion scheduled for September 26, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $4,426.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3 mL) on June 3, 2025, with an ultimate completion date of June 4, 2025. The order was fulfilled without a set-aside designation through open competition and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,396.14 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $11,488.68 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pen 3ml, with an ultimate completion date of November 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on November 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and...
- The Defense Logistics Agency awarded a $49,303 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with an ultimate completion date of September 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 ml) with a ceiling value of $2,455.66. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 15, 2025, and performance to be executed in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,005.06 delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml), with an ultimate completion date of July 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEDDZDelivery Order
The Defense Logistics Agency awarded a $11,098.60 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL). The contract is non-set-aside and competitively awarded, with performance scheduled for completion by June 4, 2025, at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables the contractor to supply a broad range of pharmaceuticals, specialty medications, vaccines, and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare entities. The company's extensive federal contract portfolio demonstrates its capability to fulfill competitive procurement requirements across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, and specialized medical supplies. The Ozempic delivery under this order supports the DLA's ongoing mission to ensure adequate pharmaceutical supply chains for Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 6/3/25 |